Gain Contingency, Number of Defendants

No definition available.

Name:	pfe_GainContingencyNumberofDefendants
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Without Court Proceedings, Number

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsWithoutCourtProceedingsNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_LitigationCaseAxis=pfe_NHSScotlandvs.DrReddysMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments (Patent Litigation) (Details)	1 Months Ended						3 Months Ended
	Jul. 31, 2020 plaintiff	Jan. 31, 2020 Patents	Mar. 31, 2019 Patents	Jun. 30, 2018 Patents	Oct. 31, 2017 Patents	Mar. 31, 2017 Patents	Apr. 30, 2017 Defendant Patents
NHS Scotland vs. Dr Reddy's [Member] \| Pending Litigation [Member] \| Patent Infringement [Member]
Gain Contingencies [Line Items]
Number of plaintiffs \| plaintiff	14
Patent Infringement [Member]
Gain Contingencies [Line Items]
Number of patents which the Patent Trial and Appeal Board refused to initiate proceedings					2
Patent Infringement [Member] \| Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon				1
Patent Infringement [Member] \| Pfizer Versus Generic Companies [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon			2
Patent Infringement [Member] \| Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		3
Patent Infringement [Member] \| Xeljanz [Member] \| Pfizer Versus Zydus [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon						3
Patent Infringement [Member] \| Eliquis [Member] \| Pfizer and BMS Versus Several Generic Manufacturers [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon							3
Number of defendants \| Defendant							25
Number of patents allegedly infringed upon due to expire December 2019							1